Business
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney di
About this update from Davita Inc.
[{"type":"image","alt":"R1 Therapeutics","displaySize":"","headline":null,"caption":"R1 Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/4330cf90f3e78262ca505905ff7e073d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kiPFaEQsxikQmaAEAlajIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4330cf90f3e78262ca505905ff7e073d","width":300,"height":90}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate ","length":247,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":516,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals, Ltd. (“Alebund”). The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and U.S. Renal Care.","length":636,"tagName":"p"},{"type":"text","content":"Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year.","length":181,"tagName":"p"},{"type":"text","content":"AP306 is a first-in-class, pan phosphate transporter inhibitor in development as a monotherapy for the treatment of h...